Harnessing AI for Precision Medicine: Transforming Care for Every Patient

Date: October 13, 2026 - October 13, 2026
Type: In-person
Location: Asia
Areas of Interest: Oncology

Shaping the Future of Precision Oncology in Malaysia

13 October 2026 | 3:00 PM | Prince Court Medical Centre (PCMC), Kuala Lumpur

Join leading voices from across Malaysia’s healthcare and oncology community for an afternoon exploring how precision oncology can move from vision to clinical impact.

Hear perspectives from IHH, the Ministry of Health, SOPHiA GENETICS and leading clinicians on the evolution of precision oncology in Malaysia — from genomic insights and AI-powered innovation to real-world clinical practice.

A Milestone for Precision Oncology

A key highlight of the afternoon will be the Memorandum of Understanding signing between Premier Integrated Labs (PIL) and SOPHiA GENETICS, marking a shared commitment to advancing precision medicine and strengthening Malaysia’s precision oncology ecosystem.

The programme will also feature clinical cases, expert perspectives and opportunities to connect with colleagues shaping the future of cancer care.

Programme

Session	Activity
Opening	Shaping the Future of Precision Oncology in Malaysia
IHH Keynote	IHH’s Vision for Precision Oncology and the Future of Cancer Care
MOH	Malaysia’s Precision Oncology Journey: From Vision to Access
SOPHiA GENETICS	AI-Powered Precision Oncology: From Genomic Data to Clinical Impact
MOU Signing	PIL × SOPHiA GENETICS: A Partnership for the Future of Precision Oncology
Clinical Cases	Precision Oncology in Practice: From Genomic Insights to Patient Care
Networking	Building the Precision Oncology Ecosystem in Malaysia

Register your Interest

We would be delighted to have you join us for this important milestone in Malaysia’s precision oncology journey.

Book a Meeting

URL

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Company(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services